Evolus to Participate in the H.C. Wainwright Global Investment Conference
May 11 2022 - 8:45AM
Business Wire
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a
customer-centric approach focused on delivering breakthrough
products, today announced that members of its management team will
be participating in the H.C. Wainwright Global Investment
Conference.
Event:
H.C. Wainwright Global Investment
Conference
Date:
Tuesday, May 24, 2022
Time:
9:00-9:30 am ET
An audio webcast of this event will be available on the investor
relations section of Evolus’ website at www.evolus.com. A replay of
the webcast will be available for 90 days after the date of the
presentation.
About Evolus, Inc.
Evolus (Nasdaq: EOLS) is a performance beauty company with a
customer-centric approach to delivering breakthrough products.
Approved in 2019 by the U.S. Food and Drug Administration, Jeuveau®
(prabotulinumtoxinA-xvfs) is the first and only neurotoxin
dedicated exclusively to aesthetics and manufactured in a
state-of-the-art facility using Hi-Pure™ technology. Jeuveau® is
powered by Evolus’ unique technology platform and is designed to
transform the aesthetic market by eliminating the friction points
existing for customers today. Visit us at www.evolus.com and follow
us on LinkedIn, Twitter, Instagram or Facebook.
Jeuveau® is a registered trademark of Evolus, Inc.
Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220511005100/en/
Investor/Media
Contact: David K.
Erickson, Evolus, Inc. Vice President, Investor Relations
Tel: 949-966-1798
Email:
david.erickson@evolus.com
Evolus (NASDAQ:EOLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Evolus (NASDAQ:EOLS)
Historical Stock Chart
From Apr 2023 to Apr 2024